CD83 is a Targetable Inflammatory Marker of KRAS Mutant Cells in Myeloid Malignancies

KRAS mutations are enriched in resistant myeloid neoplasms and are associated with poor prognosis. The lack of distinct surface markers makes it difficult to distinguish RAS-mutant leukemic stem and progenitor cells from normal counterparts and define their functional properties within mixed human bone marrow populations. Thus, Genotyping of Transcriptomes was performed across a spectrum of myeloid malignancies and showed that KRAS mutant cells formed a distinct inflammatory, stem/progenitor-like population characterized by CD83 overexpression. CD83+ mutant cells displayed impaired differentiation, whereas CD83 blockade in a novel transplantable KrasG12D mouse model reduced leukemogenic potential and prolonged survival. Selective KRASG12D inhibition in patient samples and in vivo promoted erythroid differentiation, reduced monocytosis and tumor burden, and reversed inflammatory cytokine production. The transplantable KrasG12D model recapitulated human disease, including extramedullary granulocytic tumors, and responded to treatment with a selective KRASG12D inhibitor. These findings identify CD83 as a novel therapeutic target across KRASG12D-mutant myeloid neoplasms.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-19
DOI
https://doi.org/10.21203/rs.3.rs-11528826/v1
Primary Topic
Acute Myeloid Leukemia Research
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

CD83 is a Targetable Inflammatory Marker of KRAS Mutant Cells in Myeloid Malignancies

Amittha Wickrema, Divij Verma, Rahul Sanawar, Srinivas Aluri et al.
Research Square
Acute Myeloid Leukemia Research
preprint

CD83 is a Targetable Inflammatory Marker of KRAS Mutant Cells in Myeloid Malignancies

Amittha Wickrema, Divij Verma, Rahul Sanawar, Srinivas Aluri, Marina Y Konopleva, Milagros Carbajal, Leah Kravets, Lindsay M. LaFave, Amit Verma, Shanisha A. K. Gordon, Mirca Saras Saurty-Seerunghen, Hussein A. Abbas, Ulrich G. Steidl, Mendel Goldfinger, Ariel A. Fromowitz, Chi-Lam Poon, Swathi-Rao Narayanagari, Aditi Shastri, Anna S. Nam, Srabani Sahu, Rongbao Zhao, Olivia Sakaguchi, Jinghang Zhang, Jingli Wang, Ritesh Agarwal
preprint en

Abstract

KRAS mutations are enriched in resistant myeloid neoplasms and are associated with poor prognosis. The lack of distinct surface markers makes it difficult to distinguish RAS-mutant leukemic stem and progenitor cells from normal counterparts and define their functional properties within mixed human bone marrow populations. Thus, Genotyping of Transcriptomes was performed across a spectrum of myeloid malignancies and showed that KRAS mutant cells formed a distinct inflammatory, stem/progenitor-like population characterized by CD83 overexpression. CD83+ mutant cells displayed impaired differentiation, whereas CD83 blockade in a novel transplantable KrasG12D mouse model reduced leukemogenic potential and prolonged survival. Selective KRASG12D inhibition in patient samples and in vivo promoted erythroid differentiation, reduced monocytosis and tumor burden, and reversed inflammatory cytokine production. The transplantable KrasG12D model recapitulated human disease, including extramedullary granulocytic tumors, and responded to treatment with a selective KRASG12D inhibitor. These findings identify CD83 as a novel therapeutic target across KRASG12D-mutant myeloid neoplasms.

Research Square
Albert Einstein College of Medicine (US), Montefiore Medical Center (US), The University of Texas MD Anderson Cancer Center (US), University of Chicago (US), Weill Cornell Medicine (US), Montefiore Einstein Comprehensive Cancer Center (US)
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon